AgomAb Therapeutics (AGMB) Stock Price, News & Analysis

Company Overview

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company's name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones. The company emphasizes creating antibody formats that mimic or enhance natural ligand-receptor interactions to restore or improve biological signaling. While specific programs and indications evolve with research and regulatory progress, AgomAb’s platform is positioned to address therapeutic areas that may benefit from receptor activation rather than inhibition.

AgomAb conducts its research and development through in-house scientific teams and may pursue strategic partnerships or collaborations to advance lead candidates toward clinical testing and commercialization. Public disclosures such as SEC filings, company press releases and investor presentations are the primary sources for up-to-date information on the company’s pipeline, program timelines, corporate leadership and geographic footprint. Investors and analysts should consult those documents for specific details about AgomAb’s ongoing programs and corporate developments.

Key Stats

• Today's Range: $13.59 to $14.94
• 50-Day Range: $11.60 to $17.82
• 52-Week Range: $8.75 to $17.82
• Volume: 407,876 shs
• Average Volume: 142,252 shs
• Market Capitalization: $537.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.50
• Consensus Rating: Moderate Buy

AgomAb Therapeutics Stock Analysis - MarketRank™

AgomAb Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 244th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AgomAb Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

AgomAb Therapeutics has a consensus price target of $37.50, representing about 152.9% upside from its current price of $14.83.

Amount of Analyst Coverage

AgomAb Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AgomAb Therapeutics are expected to decrease in the coming year, from ($1.76) to ($2.06) per share.

Price to Book Value per Share Ratio

AgomAb Therapeutics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.60% of the float of AgomAb Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

AgomAb Therapeutics has a short interest ratio ("days to cover") of 7.74.

Change versus previous month

Short interest in AgomAb Therapeutics has recently decreased by 21.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AgomAb Therapeutics does not currently pay a dividend.

Dividend Growth

AgomAb Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.13

News Sentiment

AgomAb Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for AgomAb Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added AgomAb Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AgomAb Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

AgomAb Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGMB
• CIK: 2020932
• Web: www.agomab.com
• Phone: (323) 302-3530
• Fax: N/A
• Employees: 62
• Year Founded: 2017

Price Target and Rating

• Average Price Target for AgomAb Therapeutics: $37.50
• High Price Target: $60.00
• Low Price Target: $28.00
• Potential Upside/Downside: +152.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.88
• Quick Ratio: 6.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.51 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 36,240,000
• Free Float: N/A
• Market Cap: $537.44 million
• Optionable: N/A
• Beta: N/A